Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Thorac Oncol. 2020 Dec 8;16(3):419–427. doi: 10.1016/j.jtho.2020.11.021

Figure. 4. Comparing the predictive powers of TMB-H vs the compound signature in ICB-treated NSCLC patients.

Figure. 4.

A). OS levels of the MSK-TMB patients with high (≥10) and low (<10) TMB values. HR=0.71 (95% [CI]:0.52–0.94).

B). OS levels in ICB treated MSK-TMB NSCLC patients with TMB-H (≥10) and TMB-L (<10) further stratified according to groups with no compound (NC) or with compoud mutation signature (C).

P-values calculated by use of logrank test.